Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Novel library of synthetic NGF agonists that bind in a highly specific manner the tropomyosin kinases (Trk) receptor. More
A novel drug target and peptide(s) designed to inhibit protein synthesis by specifically preventing formation of the 43S preinitiation complex More
Treatment of Skin and Epithelial Tumors Using Intralesional Injection of Combined Antigens More
The primary function of ADAMTS-2 is the maturation of procollagen type I, II and III. Results obtained by in vitro testing, ex vivo model, and in vivo model support the hypothesis that ADAMTS-2 is an anti-angiogenic factor. More
The University of Edinburgh has developed a new method of screening for polymorphs and solvates of drug compounds that has potential to revolutionise the way polymorph screening is conducted. More
Experiments in vitro demonstrate that these novel SMO inhibitors potentially suppress the growth of cancer cells and inhibit the expression of the HH/PTCH pathway genes. More
VEGF111, a novel naturally occurring isoform of human VEGF-A, was recently cloned. VEGF111 is active in terms of activation of VEGF receptors, induction of endothelial cells multiplication and stimulation of vascularisation in vitro and in vivo. As r More
This technology will show quantatively the damage done to the skin by UVA rays and measure how well these are being blocked. More
Colloid scientists at the University of Edinburgh have invented a new generic route to gel formulation, involving particles suspended in fluid-bicontinuous mixture of two solvents. More
An effective treatment of inflammatory skin diseases (Psoriasis), fertility, nicotine damage, and degenerative diseases. More
Your selection
Browse By
- Industry sector
- Assay systems
- Diagnostic test systems
- Gene therapy
- Human diagnostics
- Human therapeutics
- Nanotechnology
- Other
- Research supplies
- Stem cells
- Therapeutic target
- Acne
- Actinic keratosis
- Alopecia
- Bacterial infection
- Burns
- Chronic idiopathic urticaria
- Cosmetic procedures
- Dermal ulcers
- Dermatitis, allergic
- Dermatitis, atopic
- Dermatological (other)
- Dermatosis
- Eczema
- Fungal infection
- Hirsutism
- Human B19 parvovirus
- Hyperkeratosis
- Ichthyosis
- Impetigo
- Insect bite
- Keloids
- Lupus
- Male pattern baldness
- Paget's disease
- Photodamage
- Pruritis
- Psoriasis
- Scleroderma
- Shingles
- Skin infection (other)
- Ulcer, diabetic
- Urticaria
- Wound healing
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us